Acurx Expands Patent Portfolio with Korean DNA Polymerase IIIC Inhibitor Grant

Event summary

  • Korean Intellectual Property Office (KIPO) granted Acurx a new patent for DNA Polymerase IIIC inhibitors, expanding its global IP portfolio.
  • Acurx now holds four U.S. patents and granted patents in Israel, Japan, India, Australia, and Korea for its ACX-375C program.
  • Lead candidate ibezapolstat is Phase 3-ready for oral treatment of acute C. difficile infection (CDI).
  • Company plans groundbreaking clinical trial for multiply-recurrent CDI (rCDI) with ibezapolstat.
  • Preclinical pipeline includes candidates for ABSSSI, pneumonia, bacteremia, bone/joint infections, and inhalational anthrax.

The big picture

Acurx's expanded patent portfolio strengthens its position in developing novel antibiotics targeting difficult-to-treat Gram-positive bacterial infections. The strategic focus on DNA Polymerase IIIC inhibitors positions the company to potentially disrupt treatment paradigms for conditions like CDI and anthrax, while its AI-supported drug discovery platform may accelerate pipeline development. The global patent coverage enhances Acurx's ability to commercialize its lead candidate ibezapolstat and supports its long-term growth strategy in the infectious disease space.

What we're watching

Regulatory Approval
Whether ibezapolstat will successfully advance through Phase 3 trials and secure FDA/EMA approval for acute CDI treatment.
Market Differentiation
How Acurx's microbiome selectivity data will position its antibiotics against competitors like linezolid in the treatment of Gram-positive infections.
Pipeline Progression
The pace at which Acurx can transition its preclinical candidates into clinical development, particularly for ABSSSI and anthrax indications.